Aktis Oncology Launches with $318M IPO to Advance Radiopharmaceutical Cancer Therapies
Aktis Oncology’s sizeable IPO reflects growing investor interest in innovative radiopharmaceutical approaches for cancer. The company’s pipeline focuses on miniprotein radioconjugates aimed at targeted radiation delivery, and it benefits from a discovery partnership with Eli Lilly.
IPO Details and Strategic Focus
- Aktis Oncology raised $318 million in its initial public offering, the first biotech IPO of 2026.
- The company focuses on developing miniprotein radioconjugates for targeted cancer radiation treatment.
- A discovery partnership with Eli Lilly underpins Aktis’ pipeline development efforts.
Significance for Cancer Radiopharmaceuticals
- Radioconjugates are a promising modality offering targeted delivery with potential advantages over current radiation approaches.
- The IPO proceeds are intended to support advancing multiple candidates through clinical development and expanding pipeline reach.
Source: MedCity News
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.